LLY
Lilly’s pipeline shopping spree continues
Eli Lilly is back at the drug-discovery buffet. On Tuesday, the company announced a strategic research collaboration and license deal with Abbisko Therapeutics aimed at finding and developing new medicines across multiple disease targets.
Abbisko will handle discovery and early-stage development for programs Lilly picks, while Lilly gets to lean on its global development and commercialization muscle. In biotech terms, that’s basically: you bring the science, we’ll bring the scale.
The money is in the milestones
The headline number here is the one that makes everyone sit up straighter: Abbisko could earn up to about $1.9 billion through upfront cash plus development, regulatory, and commercial milestone payments, along with tiered royalties on future sales.
That doesn’t mean Lilly is writing a $1.9 billion check today. But it does mean the company is willing to pay big if the partnership coughs up something worth bringing to market. For a drug giant, that’s the price of keeping the pipeline from looking like a tumbleweed convention.
Why investors should care
This deal builds on an existing relationship between the two companies and follows other recent Lilly licensing moves, including agreements with Hanmi Pharm and Haisco. Translation: Lilly is clearly shopping internationally for fresh shots on goal instead of relying only on in-house discovery.
For shareholders, that can be a good thing. More partnerships can mean more pipeline optionality, more shots at future blockbusters, and less dependence on any single drug story. Big picture: Lilly doesn’t just want to sell medicines — it wants to stockpile them before the next blockbuster race gets even more expensive.